1BMY Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details

1BMY fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	2/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 63.9% below our estimate of its fair value

Earnings are forecast to grow 7.28% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Dividend of 5.15% is not well covered by earnings

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Bristol-Myers Squibb Company Competitors

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.7b

Chugai Pharmaceutical

TSE:4519

JP¥12.4t

GSK

LSE:GSK

UK£56.9b

Sanofi

ENXTPA:SAN

€111.0b

Price History & Performance

Summary of share price highs, lows and changes for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$42.85
52 Week High	US$57.80
52 Week Low	US$36.62
Beta	0.40
1 Month Change	-2.00%
3 Month Change	-20.77%
1 Year Change	2.50%
3 Year Change	-42.05%
5 Year Change	-28.16%
Change since IPO	-17.95%

Recent updates

Shareholder Returns

	1BMY	IT Pharmaceuticals	IT Market
7D	-2.3%	-3.0%	3.1%
1Y	2.5%	-18.7%	13.6%

Return vs Industry: 1BMY exceeded the Italian Pharmaceuticals industry which returned -19% over the past year.

Return vs Market: 1BMY underperformed the Italian Market which returned 12.5% over the past year.

Price Volatility

Is 1BMY's price volatile compared to industry and market?
1BMY volatility
1BMY Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.9%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1BMY has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1BMY's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
1BMY fundamental statistics
Market cap	€85.23b
Earnings (TTM)	€4.89b
Revenue (TTM)	€42.95b

18.1x

P/E Ratio

2.1x

P/S Ratio

Is 1BMY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1BMY income statement (TTM)
Revenue	US$47.64b
Cost of Revenue	US$12.06b
Gross Profit	US$35.58b
Other Expenses	US$30.16b
Earnings	US$5.42b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 31, 2025

Earnings per share (EPS)	2.66
Gross Margin	74.69%
Net Profit Margin	11.38%
Debt/Equity Ratio	285.1%

How did 1BMY perform over the long term?

See historical performance and comparison

Dividends

5.1%

Current Dividend Yield

91%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 18:06
End of Day Share Price	2025/05/12 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 46 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Charles Butler	Barclays